Flucytosine Suppliers & Bulk Manufacturers
Available Forms: Capsules / Oral Solution
Available Strengths: 250 mg, 50 mg/ml
Reference Brands: Ancobon (USA)
Category:
Anti-fungal
Flucytosine is available in Capsules / Oral Solution
and strengths such as 250 mg, 50 mg/ml.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Flucytosine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Flucytosine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Flucytosine, also known as 5-fluorocytosine (5-FC) and marketed under the brand name Ancobon, is an antifungal medication used for the treatment of serious systemic fungal infections, including Candida infections and cryptococcosis. As an antimetabolite, flucytosine specifically targets fungal cells by interfering with DNA and RNA synthesis, while sparing mammalian cells, which enhances its safety profile.
Flucytosine is commonly administered in combination with another antifungal agent, such as amphotericin B, to prevent the development of fungal resistance. Its use as a monotherapy is generally discouraged due to the risk of resistance. The medication can be administered orally or intravenously, depending on the severity and type of infection.
Clinical monitoring is essential during treatment, particularly because flucytosine is primarily excreted by the kidneys. Dose adjustments are required in patients with impaired renal function to minimize the risk of toxicity. With careful medical supervision, flucytosine provides an effective option for managing severe and systemic fungal infections, offering both efficacy and a favorable safety profile.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing